Comparative in vitro activity of the new oral cephalosporin BMY-28100.
Using a broth microdilution method, the in vitro activity of BMY-28100 against 365 clinical strains of commonly isolated bacteria was determined. BMY-28100 showed good activity against streptococci, methicillin-susceptible staphylococci, Salmonella spp., Shigella spp., and beta-lactamase producing Branhamella catarrhalis and Haemophilus influenzae. Against susceptible strains of these organisms, BMY-28100 showed activity comparable to that of penicillin G, ampicillin, co-trimoxazole, erythromycin, cefaclor, doxycycline and amoxicillin/potassium clavulanate. BMY-28100 had moderate activity against Arizona hinshawii and poor activity against Campylobacter jejuni and Yersinia enterocolitica.
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects*; D002511:Cephalosporins / Q000494:pharmacology*; D004064:Digestive System / Q000382:microbiology; D006801:Humans; D008826:Microbial Sensitivity Tests; D012137:Respiratory System / Q000382:microbiology; D012867:Skin / Q000382:microbiology; D000097670:Cefprozil
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000097670:Cefprozil